CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Ran Yam, of NovaSight, discusses positive topline study data for the CureSight amblyopia therapy device.
According to Yam, the device was noninferior to patching, with 80% of children in the CureSight treatment group showing a two-line improvement in visual acuity, which was better than the results in the patching treatment group.